Intraoperative Imaging of Pulmonary Adenocarcinoma

VA Office of Research and Development logo

VA Office of Research and Development

Status and phase

Withdrawn
Phase 1

Conditions

Lung Cancer

Treatments

Drug: EC17 imaging contrast agent

Study type

Interventional

Funder types

Other
Other U.S. Federal agency

Identifiers

NCT02653612
CLNB-009-14F

Details and patient eligibility

About

The goal is to improve surgery by preventing tumor cells from being left behind at the time of surgery. This includes finding residual tumor cells in the wound after surgery.

Full description

The goal is to improve the intraoperative identification of tumor cells at positive margins and regional metastases that may be missed by a surgeon during a pulmonary resection. Improved identification of tumor cells will result in superior disease clearance and more accurate clinical staging. The investigators hypothesize that targeted fluorescent imaging during surgery will improve identification of positive margins and metastases. Since folate receptor alpha (FR ) is expressed on 55% of resectable lung cancer, the investigators will utilize a fluorescent probe that targets these tumors. As real-time imaging provides more information to the surgeon, more personalized and directed operations can be conducted. This work will allow for more preservation of normal tissue, decreased morbidity, decreased surgical time, increased surgical confidence, improved cancer detection, decreased unnecessary surgery and ultimately improved tumor free survival. This technology should transform clinical surgery from an art that depends fully on the human factor to a procedure that has precision and fail safes.

Sex

All

Ages

18 to 99 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • lung cancer
  • surgical candidate
  • operable
  • resectable

Exclusion criteria

  • no allergies to contrast dyes

Trial design

Primary purpose

Diagnostic

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

0 participants in 1 patient group

Experimental Arm
Experimental group
Description:
This cohort will receive the contrast agent
Treatment:
Drug: EC17 imaging contrast agent

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems